The current healthcare environment reshapes the three key factors in market access – value, evidence, and commercial positioning of new treatments. Greater emphasis on patient centricity meets budget cuts. Leading to a sharper focus on demonstrating patient benefit value specific… Continue Reading
Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does… Continue Reading
The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered… Continue Reading
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when… Continue Reading
Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care… Continue Reading
